Poor and/or biased study interpretation does not negate the positive uses of IV magnesium post myocardial infarct (MI)

Posted by Dr Dan Carter, June 29, 2016
I was looking over a Facebook post today about the efficacy of IV Mg for MI, and it piqued my interest in looking at more recent research, since the post referred to studies from 1986 and 1992.

In double-blind, placebo-controlled study, they looked at 273 patients who were admitted to the hospital for a heart attack. The study revealed that after 4 weeks, the people who received magnesium, only 7% died versus 19% who did not get magnesium; magnesium cut the death rate by 63%.
What was interesting is the fact that the study indicated that patients were generally given less than the 2 cc of magnesium which is the recommended dose.
Furthermore, the injection of magnesium decreased arrhythmias by 55%. Arrhythmia is a major concern following MI. [Abstract: In a double-blind, placebo-controlled study, 273 patients with suspected acute myocardial infarction (AMI) were randomised to receive either magnesium intravenously or placebo immediately on admission to hospital. Of 130 patients with proven AMI 56 received magnesium and 74 received placebo. During the first 4 weeks after treatment mortality was 7% in the magnesium group and 19% in the placebo group. In the magnesium group 21% of patients had arrhythmias that needed treatment, compared with 47% in the placebo group. No adverse effects of intravenous magnesium were observed. [PMID: 2868254]

Another study in the same medical journal showed that magnesium produced a 24% reduction in the number of deaths in one month after the heart attack.
Besides the proven benefits for victims of a heart attack, another study showed patients who were given IV magnesium had a 76% reduction in death from a fatal blood clot. This study also showed that aspirin was of no benefit. [PMID: 1351547]

A PubMed search for the terms IV Magnesium and Myocardial Infarct came up two papers I’ll discuss briefly.

A 2015 rat study where MI was induced by isoprenaline used MgSO4 270 mg/kg intraperitoneally or an equivalent volume of physiological saline. The study authors concluded that although Mg(2+) had no detrimental effects on electrical or hemodynamic activity in ISO-induced MI, the lack of infarct prevention may detract from its utility in MI therapy. [PMID: 26212925] This is hardly surprising since the principle application of Mg for MI is prevention of arrhythmia, and one of the physiological actions of Mg is to potentiate the coagulant activities of clotting factor IV. [PMID: 8621478] It would appear that the authors looked at the wrong outcomes.

A 1995 article in the journal circulation, however, found that early treatment with MgSO4 resulted in both a significant reduction in lethal arrhythmias and infarct size when subjects (swine in this case) were treated soon after infarct initiation. To wit:
“ Lethal arrhythmias were significantly reduced in the Mg-early group. Infarct size was determined by vital staining. Infarct size was 0.16±0.05 g/kg body wt (Mg-early), 0.35±0.08 g/kg (Mg-late), and 0.42±0.04 g/kg for the control group” [PMID: 7586365]

Since Cochrane reviews have become popular, it is evident in some cases that meta-analysis can also lead to questionable conclusions. In their usual serious style, they state that mortality and morbidity from acute myocardial infarction (AMI) remain high, and that intravenous magnesium started early after the onset of AMI is thought to be a promising adjuvant treatment. But conflicting results from earlier trials and meta-analyses warrant a systematic review of available evidence. [PMID: 17443517] They go on to conclude that:
(1) it is unlikely that magnesium is beneficial in reducing mortality both in patients treated early and in patients treated late, and in patients already receiving thrombolytic therapy.
(2) it is unlikely that magnesium will reduce mortality when used at high dose (>=75 mmol)
(3) magnesium treatment may reduce the incidence of ventricular fibrillation, ventricular tachycardia, severe arrhythmia needing treatment or Lown 2-5, but it may increase the incidence of profound hypotension, bradycardia and flushing
(4) the areas of uncertainty regarding the effect of magnesium on mortality remain the effect of low dose treatment (< 75 mmol) and in patients not treated with thrombolysis.   Conclusions 1 and 2 can be refuted by the Woods study in Lancet [PMID: 1351547] as it was a large randomised, double blind, placebo controlled study utilizing 2316 subjects. Woods concluded that 28-day mortality did not indicate any effect modification by thrombolysis or aspirin, or by previous treatment with beta blockers and calcium antagonists. Conclusion 3 would infer that serious MI after-effects such as arrhythmia are minimized in the review, while side effects well understood and avoidable by those familiar with IV nutrient therapy are maximized. Conclusion 4 (and 2) utilized Mg doses of >=75 mmol, which if my calculations are correct [http://www.mgwater.com/convert.shtml] comes out at 36.946 mL of 50% MgSO4. That is a dose at which blood electrolyte concentration monitoring is absolutely necessary. Safe dose and infusion rate can be found at https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8f775557-e414-4119-89a8-c19334f5f116&type=display Lower doses of Mg, such as those used in IV nutrient therapy, have been shown to be effective in controlling arrhythmia, especially in combination with taurine.

After looking at readily available literature, I would posit that Mg use after myocardial infarct is indeed useful, especially when administered as soon as possible after the MI. The Cochrane review seems to show bias in favor of pharmaceutical agents rather than a relatively inexpensive mineral such as magnesium, a common finding in a medical journal system dominated by drug advertising and pharmaceutical company funding of CME events (this is a simple fact, not a judgment of the journal and medical education system lacking merit).

Scroll to Top
Vertisis Custom Pharmacy

Vertisis Custom Pharmacy

Vertisis is one of the most unique sterile-injectable compounding pharmacies in the United States. Our focus is on going “above and beyond” traditional compounding pharmacies by raising the standards of 503A compounding pharmacies to include exceptional products, unique delivery, advanced education, and an amazing relationship with health care providers with a seamless delivery of care. Vertisis originates from over 20 years of clinical practice in custom compounded pharmaceutical agents and over 100 years of combined compounding pharmacy experience with clinical usage of the latest technologies. We have intimate knowledge of hundreds of thousands of custom compounded pharmaceutical treatments with a team of knowledgeable pharmacists to help answer your questions.

Sign up to receive seminar news and updates!

TransLite LLC

345 Commerce Green Blvd.
Sugar Land, TX 77478

TransLite LLC is a small high tech company comprising dedicated people who design, manufacture and sell medical devices that can help reduce the pain and trauma to patients during venous access and treatment of varicose veins.
Our mission is
• To design innovative medical products that help mankind
• Produce highest quality products at affordable prices
• Provide excellent service and support to our customers
We are accomplishing our mission by providing Veinlites® to healthcare professionals all over the world. Since 1999, over 40,000 medical professionals have come to rely on Veinlite® vein finders for simple and consistent one-stick vein access. If failed IV attempts are a daily occurrence among your team, don’t get frustrated…get Veinlite®!

Phone: (281) 240-3111
Fax: (281) 240-3122

With Veinlite® products, you can locate and access veins within seconds – even in the most difficult patients whether due to their age, weight, or skin tone.
Please visit www.veinlite.com or contact us for more information at info@veinlite.com or 281-240-3111.

McGuff Family of Companies

Legacy Corporate Contributor
2921 W. MacArthur Blvd., Suite 142
Santa Ana, CA 92704

McGuff Company Inc. is a wholesale distributor of over 5,000 competitively prices pharmaceuticals, IV related products, physician office & exam room supplies and an extensive oral nutritional line to support your patient’s treatments. Our experienced customer service staff are experts at finding hard-to-find products. We maintain close relations with both large and small manufacturers of quality products to assure we will meet all of your needs. Competitive prices for over 35 years!

Verified-Accredited Wholesale Distributor (VAWD)
Phone (800) 854-7220 Toll Free
Fax (714) 540-5614 Toll Free Fax

McGuff Compounding Pharmacy Services specialty pharmacy compounding all dosage forms – preservative-free injections, amino acids, natural hormones and custom formulations all at competitive prices. Injectables are tested for particulates, sterility and endotoxins.

Accredited by the Pharmacy Compounding Accreditation Board (PCAB) &
Independently certified as ISO 9001-2008
Phone (877) 444-1133 Toll Free
Fax (877) 444-1155 Toll Free Fax


P.O. Box 308
Ada, MI 49301-0308
Toll-Free: (844) 733-7847

SterileDrugs.com is committed to helping medical providers and practices overcome the challenges of acquiring the very best custom and non-custom medications. By contracting with multiple FDA-Registered Outsourcing Facilities (503B pharmacies), our goal is to be your source, resource, and solution for the highest quality medications at the most competitive prices.

About SterileDrugs.com
SterileDrugs.com partners with 503B pharmacies that specialize in manufacturing medications for IV Nutritional Therapy, Hormone Replacement Therapy & Weight Loss. Our pharmacy partners are held to the highest quality standards by the FDA and comply with USP 795, 797 & cGMP guidelines. For a complete list of the medications we offer, as well as pricing, please contact us at: www.steriledrugs.com or 844-73DRUGS

Doctor’s Data, Inc.

3755 lllinois Avenue.
St. Charles, IL 60174 – 2420 USA
US and Canada (800) 323-2784

Doctor’s Data, Inc. has provided innovative specialty testing to healthcare practitioners around the world from our advanced, CLIA-licensed clinical laboratory since 1972. Choose DDI to help you assess and treat heavy metal burden, nutritional deficiencies, gastrointestinal function, hormone and HPA/adrenal function status, cardiovascular risk, liver and metabolic abnormalities, and more.

Simply O3

We help you get started with ozone therapy in your clinic – Grow your income and improve patient outcomes.  Download the DEFINITIVE Guide to Getting Started with Ozone Therapy by going to www.DrsOzone.com/Guide.  Full training and support available  Equipment has a 6 month money back guarantee and is easy to use.  Go download your FREE guide to getting started now at www.drsozone.com/guide.

Merit Pharmaceutical

2611 N. San Fernando Road
Los Angeles, CA 90065
Phone (800) 421-9657 Toll Free US & Canada
Fax (323) 227-4833

Offering IV infusion from Merit? Getting your med/surg/pharma from us? Your colleagues are and they have higher profits. Merit supplies Anti Aging/Aesthetic/Integrative practitioners better prices on the products you use. Call us and learn why successful clinics partner with Merit. IV Therapy Nutrition/Hydration, Weight Loss, Hormones, IV solutions, PRP products, exam/surgical supplies and more. Merit offers pharmaceuticals (2, 3, 3N, 4), and related medical products. www.meritpharm.com or (800) 69-MERIT

Perfect Balance

Perfect Balance, Inc. is providing new hope for cancer victims. We have a proprietary formula which destroys the enzymatic protection of cancer cells and greatly increases NK cell activity. By inhibiting the production of Nagalase the cancer cell can no longer stop the immune system  from doing its job. Innate GC Maf resumes and rapid tumor breakdown is evident. Salicinium enhances NK cell activity and has been shown to kill
both Circulating Tumor Cells and Cancer Stem Cells.

Perfect Balance, Inc. has been in business for more than 25 years and has spent most of that time working in the field of cancer

AMARC Enterprises / POLY-MVA

Contributor, Sponsor and Supporter
San Diego, CA 92021
Phone (866) 765-9682 Toll Free or (619) 447-6500
Fax (619) 447-6501

AMARC Enterprises and Poly-MVA endeavor to treat people honestly and with integrity, and to promote healthy living through our search for the highest quality products. We seek to improve the health and quality of life through practitioners and patients in integrative and regenerative medicine. We know that through smart and targeted therapies with efficacious products people can live fuller, longer and happier lives. Since 2001, AMARC and PolyMVA have been providing quality, FDA compliant products that have helped thousands of people achieve better health.

Lipoic Acid Mineral Complex is the key component that makes Poly-MVA a uniquely-formulated supplement, containing a proprietary blend of the mineral palladium bonded to alpha-lipoic acid, Vitamins B1, B2 and B12, formyl-methionine, N-acetyl cysteine, plus trace amounts of molybdenum, rhodium, and ruthenium. Poly-MVA assists in boosting immune response by targeting key pathways with very specific nutrients and supports cellular metabolism. What makes Poly-MVA unique is the proprietary manufacturing process by which the mineral palladium is sequestered to lipoic acid and thiamin. No other company produces a product similar to Poly-MVA because of the preparation and bonding process through which LAMC is manufactured. The proprietary formulation of LAMC with other vitamins, minerals, and amino acids provides considerable targeted protection and mitochondrial support, helping to enable optimum functioning of multiple essential body systems.

Send in a test question for extra credit. We may add it to future exams!

Sorry. You must be logged in to view this form.